Streetbeat News

Analyst Ratings

CKPT

Lake Street analyst Thomas Flaten has maintained a 'Buy' rating on Checkpoint Therapeutics (NASDAQ:CKPT) but lowered the price target from $16 to $14.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:08 pm

OMQS

Lake Street analyst Jaeson Schmidt has maintained a 'Buy' rating on OMNIQ (NASDAQ:OMQS) but lowered the price target from $9 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:07 pm

HD

Guggenheim analyst Steven Forbes maintains a Buy rating on Home Depot (NYSE:HD) and raises the price target from $320 to $360.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:03 pm

XPOF

Guggenheim analyst John Heinbockel has maintained a 'Buy' rating on Xponential Fitness (NYSE:XPOF) but lowered the price target from $34 to $32.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:02 pm

SKY

Craig-Hallum analyst Greg Palm maintains a 'Buy' rating on Skyline Champion (NYSE:SKY) and raises the price target from $75 to $81.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:01 pm

FATE

Analysts have provided mixed ratings for Fate Therapeutics (NASDAQ:FATE) within the last quarter, with 1 bullish, 1 somewhat bullish, and 3 indifferent ratings. The average 12-month price target for the company is $6.68, representing a 22.95% decrease from the previous average price target of $8.67.

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 5:01 pm

BALY

Analysts have given mixed ratings to Ballys (NYSE:BALY) in the last quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for Ballys is $22.75, a decrease of 12.5% from the previous average of $26.00.

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 5:01 pm

SBEV

Over the past 3 months, 4 analysts have published their opinion on Splash Beverage Group (AMEX:SBEV) stock, all of them being bullish. The company has an average price target of $2.62, a decrease of 12.67% from the previous average price target of $3.00.

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 5:01 pm

MPLX

MPLX (NYSE:MPLX) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, and 3 indifferent ratings. The average price target is $41.2, indicating potential upside from the current price of $34.725. However, this average has decreased by 0.72% from the previous target of $41.50.

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 5:00 pm

A

Baird has maintained its Outperform rating for Agilent Technologies (NYSE:A) but lowered its price target from $144.00 to $140.00. Agilent's shares are currently trading down 2.59% at $122.39 per share. A move to $140.00 would represent a 14.38% increase from the current share price.

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 5:00 pm